MARKET

SABS

SABS

SAB BIOTHERAPEUTICS INC
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.75
-0.37
-5.20%
After Hours: 6.76 +0.01 +0.15% 17:58 01/14 EST
OPEN
7.01
PREV CLOSE
7.12
HIGH
7.22
LOW
6.57
VOLUME
156.18K
TURNOVER
--
52 WEEK HIGH
12.90
52 WEEK LOW
6.57
MARKET CAP
293.45M
P/E (TTM)
-11250.0000
1D
5D
1M
3M
1Y
5Y
FDA Lab Testing Confirms SAB Biotherapeutics' COVID-19 Antibody Neutralizes Omicron Variant
SAB Biotherapeutics Inc (NASDAQ: SABS) announced that SAB-185, its COVID-19 therapeutic candidate, 
Benzinga · 12/16/2021 13:06
SAB Bio jumps 19% after SAB-185 retains neutralization against Omicron variant
SAB Biotherapeutics (NASDAQ:SABS) soars 19% premarket after announcing data, demonstrating that SAB-185, a therapeutic candidate for the treatment of COVID-19 infections, retains neutralization activity against the Omicron SARS-CoV-2 variant in an in
Seekingalpha · 12/16/2021 11:22
SAB Biotherapeutics Announces SAB-185 Retains Neutralization Against Omicron SARS-CoV-2 Variant In Vitro
FDA laboratory testing confirms SAB-185 neutralizes Omicron and other variants of concern with in vitro pseudovirus model SAB’s targeted, highly potent and fully-human polyclonal antibodies continue to show broad
Benzinga · 12/16/2021 11:04
SAB Biotherapeutics' Influenza Candidate Achieves Primary Goal In Mid-Stage Study
SAB Biotherapeutics Inc (NASDAQ: SABS) has announced data from a Phase 2a challenge study of SAB-176, its investigational therapy for treating seasonal influenza.
Benzinga · 12/01/2021 16:04
The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 12/01/2021 13:36
SAB Biotherapeutics says mid-stage trial for influenza therapy met main goal
SAB Biotherapeutics (NASDAQ:SABS) announced that its Phase 2a challenge study for experimental seasonal influenza therapy SAB-176 met the primary endpoint with statistical significance. However, the shares have lost ~2.5% in the pre-market.
Seekingalpha · 12/01/2021 12:46
SAB Biotherapeutics Announces SAB-176 Met Its Primary Endpoint In Phase 2a Challenge Study In Adults Infected With Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by
Benzinga · 12/01/2021 12:09
SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus
Topline data show SAB-176 achieved statistically significant reductions in viral load and clinical symptoms and it appeared safe and well-tolerated Second clinical proof of concept achieved by DiversitAb™ platform in past two months Positive clinical resul...
GlobeNewswire · 12/01/2021 12:00
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SABS. Analyze the recent business situations of SAB BIOTHERAPEUTICS INC through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

50.00%Strong Buy
50.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SABS stock price target is 19.38 with a high estimate of 23.00 and a low estimate of 16.50.
High23.00
Average19.38
Low16.50
Current 6.75
EPS
Actual
Estimate
0.090.330.570.81
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 42
Institutional Holdings: 9.34M
% Owned: 21.49%
Shares Outstanding: 43.47M
TypeInstitutionsShares
Increased
9
927.48K
New
9
615.54K
Decreased
10
1.07M
Sold Out
5
563.96K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About SABS
SAb Biotherapeutics, Inc., formerly Big Cypress Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company offers therapeutic engine called the DiversitAb platform, to produce a new class of specifically targeted, polyclonal antibodies without the need for human donors. Its DiversitAb platform enables a production of polyclonal antibody therapies with the to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers. Its product candidates include SAB-176, SAB-185, SAB-142 and SAB-181. The Company is developing new class of immunotherapies, leveraging the native human immune response, across therapeutic categories including infectious disease immune system disorders and immuno-oncology.

Webull offers kinds of SAB Biotherapeutics Inc stock information, including NASDAQ:SABS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SABS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SABS stock methods without spending real money on the virtual paper trading platform.